Toronto, Ontario — November 13, 2025 — Leads & Copy —
Telo Genomics Corp. (TSXV: TELO), a leader in diagnostic and prognostic innovation, will present its Minimal Residual Disease (MRD) technology at the Myeloma Canada MRD Testing Implementation Summit on November 14–15, 2025.
Dr. Yulia Shifrin, Laboratory Director at Telo Genomics, will introduce initial clinical results demonstrating the power of combining Telo’s blood-based MRD workflow with the first MRD test capable of risk-profiling individual cancer cells using the TeloView® platform. This capability extends MRD beyond disease quantification, delivering prognostic insights previously unattainable with conventional methods.
Early clinical findings show that myeloma patients present distinct genomic and structural profiles at the single-cell level that correlate with relapse risk and complement their MRD status. This layer of prognostic intelligence can redefine clinical decision-making by providing a quantifiable relapse-risk score, rather than relying solely on threshold-based MRD positivity or negativity.
Dr. Sabine Mai, Co-Founder of Telo Genomics, said the summit brings together clinicians, researchers, patients, and decision-makers who can champion next-generation diagnostics for myeloma patients. She added that current MRD tools focus on measuring how much disease remains, while the TeloView® platform identifies and characterizes high-risk, aggressive cells that drive relapse early, calling it the future of MRD monitoring in multiple myeloma.
Minimal Residual Disease (MRD) is defined as the small number of cancer cells that remain in the body after treatment. Stratifying MRD cells between being in remission or active provides important actionable information for clinicians.
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma.
MRD testing is emerging as a valuable tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire – August 14, 2023).
Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time.
Next-generation therapies have increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance (MGUS) and SMM generally precede the progression to classic symptomatic MM.
While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years.
To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need.
Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US.
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches.
Telo Genomics is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of their proprietary technology have been substantiated in 160+ peer-reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease.
Their lead application, Telo-MM is being developed to provide information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer.
For further information, please contact:
Brett Maas
Managing Partner
(646) 536-7331
Brett@HaydenIR.com
7320 E. Butherus Drive
Scottsdale, AZ 85260
haydenir.com
Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements: Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274236
Source: Telo Genomics Corp.
